Compare · NVCR vs SYK
NVCR vs SYK
Side-by-side comparison of NovoCure Limited (NVCR) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVCR and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $120.38B, about 60.3x NVCR ($2.00B).
- Over the past year, NVCR is down 6.1% and SYK is down 18.5% - NVCR leads by 12.3 points.
- NVCR has been more active in the news (18 items in the past 4 weeks vs 8 for SYK).
- Both have 25 recent analyst ratings on file.
- Company
- NovoCure Limited
- Stryker Corporation
- Price
- $17.26+2.49%
- $313.99+4.11%
- Market cap
- $2.00B
- $120.38B
- 1M return
- -3.47%
- +9.97%
- 1Y return
- -6.14%
- -18.48%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 18
- 8
- Recent ratings
- 25
- 25
NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest NVCR
- NovoCure Limited filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Stafford Kristin was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)
- Chief Executive Officer Leonard Frank X sold $614,635 worth of Ordinary Shares (34,273 units at $17.93), decreasing direct ownership by 7% to 459,520 units (SEC Form 4) (withholding tax)
- Director Leung Gabriel was granted 11,610 units of Ordinary Shares, increasing direct ownership by 13% to 101,109 units (SEC Form 4)
- Director Ocean Allyson J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)
- Director Scannell Timothy J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 81% to 25,898 units (SEC Form 4)
- Director Hilleman Jeryl L was granted 11,610 units of Ordinary Shares, increasing direct ownership by 84% to 25,471 units (SEC Form 4)
- Director Hung David was granted 11,610 units of Ordinary Shares, increasing direct ownership by 57% to 32,075 units (SEC Form 4)
- Director Madden Martin J. was granted 11,610 units of Ordinary Shares, increasing direct ownership by 62% to 30,284 units (SEC Form 4)
- Director Vernon W Anthony was granted 11,610 units of Ordinary Shares, increasing direct ownership by 6% to 209,267 units (SEC Form 4)
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation